Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Accumulated Depreciation (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Accumulated Depreciation for 7 consecutive years, with $35.1 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Accumulated Depreciation fell 26.23% year-over-year to $35.1 million, compared with a TTM value of $35.1 million through Dec 2024, down 26.23%, and an annual FY2024 reading of $35.1 million, down 26.23% over the prior year.
  • Accumulated Depreciation was $35.1 million for Q4 2024 at Fate Therapeutics, down from $47.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $47.6 million in Q4 2023 and bottomed at $11.1 million in Q4 2020.
  • Average Accumulated Depreciation over 5 years is $28.2 million, with a median of $30.4 million recorded in 2022.
  • The sharpest move saw Accumulated Depreciation surged 79.31% in 2022, then decreased 26.23% in 2024.
  • Year by year, Accumulated Depreciation stood at $11.1 million in 2020, then skyrocketed by 52.73% to $16.9 million in 2021, then soared by 79.31% to $30.4 million in 2022, then soared by 56.75% to $47.6 million in 2023, then decreased by 26.23% to $35.1 million in 2024.
  • Business Quant data shows Accumulated Depreciation for FATE at $35.1 million in Q4 2024, $47.6 million in Q4 2023, and $30.4 million in Q4 2022.